Sanifit is a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, particularly in patients with end-stage kidney disease
Sanifit is a clinical-stage biopharmaceutical company focused on developing treatments for vascular calcification disorders, particularly in patients with end-stage kidney disease. Its lead compound, SNF472, targets calciphylaxis and peripheral artery disease.